Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. - Wikidata - wikimedia - TriplyDB

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.

http://www.wikidata.org/entity/Q36311839

about

Does antiviral therapy reduce complications of cirrhosis?Cancer and liver cirrhosis: implications on prognosis and management Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation.Screening for hepatitis B in patients with lymphoma.Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration Hepatitis B Serology in Patients with Rheumatic Diseases Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.Hepatitis B and elders: An underestimated issue.Rethinking the pathogenesis of hepatitis B virus (HBV) infection.Chronic hepatitis B: A wave of new therapies on the horizon.Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): a Systematic Review and Meta-analysis.Prevention and management of hepatitis B virus reactivation in cancer patients.Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.The practice pattern of hepatitis b testing in rheumatoid arthritis patients: A cross-national comparison between US and Taiwan.The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma.Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C.Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.

P2860

Q26851410-C0C35465-523F-4C4F-B7C1-ACC739C15ADB Q28068579-F4590EF2-05DE-4EB3-9A89-318ACDC67633 Q33872389-29F6EB5C-B9F2-4ACE-A8CF-1FA97087DE4B Q34212799-E6F39856-1198-4D4C-956B-D63150670211 Q34552034-4481DD3A-59F8-4E5A-9966-A6A7581284FB Q36058282-1CB22005-F836-4F2A-8CD4-B9D8E5DAFC88 Q36803202-041F9205-6569-44A4-8462-423F2F3DA45B Q36871021-0344AB93-C058-4F07-8400-CDA2BB60F62B Q36909250-F08F044F-4AF3-4CA2-9D22-B13E2FA29803 Q37291847-AA5D775D-0422-4AED-83EB-41A176DEBC3F Q37623386-55EC12CC-7EC8-4AC4-8A77-A37049BA5385 Q38084182-78FE6CFA-18B8-4ECB-8B66-7B445282C9CD Q38344214-E61DDB57-F942-4695-AD34-FDA4D2ED45A3 Q38491309-E5B6D5FA-2521-4206-95AA-544C6ECAA222 Q38538107-A66DBB41-6485-43EB-AC45-A8967304E7DE Q38566383-06839850-7AF2-40F9-A6E5-9A49D3990C45 Q38611674-C4B65A03-C43F-4E78-96CE-E9FB09E9A4C7 Q38688782-B9D6EA34-8581-4BAE-A4DC-C6FBD5656236 Q38755178-69061655-06C1-4143-8BD3-AB622091D966 Q40144152-99757B91-C2FC-4069-A0DF-1235413C5101 Q40284619-049018A5-2359-473A-98E0-09502E05BAC1 Q41107280-417FF849-4FE3-407A-8A3F-DA8DE3B55008 Q45326378-DEDC94B4-D61D-4A31-878D-A015F78670BF Q45329330-1C8F7FE6-0CAE-44F0-9207-821A46E41804 Q47562286-66BC87F7-284C-4A52-8D7D-FDD7238CA0EE Q54234367-54A61028-5C57-4C84-8917-459BD4F3CD1C

P2860

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.

http://www.wikidata.org/entity/Q36311839

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Reactivation of hepatitis B du ...... ntially fatal yet preventable.

@ast

Reactivation of hepatitis B du ...... ntially fatal yet preventable.

@en

type

label

Reactivation of hepatitis B du ...... ntially fatal yet preventable.

@ast

Reactivation of hepatitis B du ...... ntially fatal yet preventable.

@en

prefLabel

Reactivation of hepatitis B du ...... ntially fatal yet preventable.

@ast

Reactivation of hepatitis B du ...... ntially fatal yet preventable.

@en

P1433

Q36311839-FF7EB298-BF5F-45F1-96FA-AF6F93B09397

P1476

Q36311839-CE2DC110-6A35-4B25-B92C-F0EBBD9F57DC

P2093

Q36311839-4BC5AF63-8CB6-4BB4-849E-BE8AEEDBA1FB

Q36311839-69944888-8A99-474D-B7E1-FB817EBC0A41

Q36311839-69D68F1D-9A20-4894-8CCB-826CAF1FD228

Q36311839-CD101CCE-FFD8-4C61-8D2E-DDEF1E75E789

Q36311839-DCABAB36-07F3-421B-8D02-0413B4E07A41

P2860

Q36311839-1F95BFC0-21B5-4184-9CFE-6B40A3D3E348

Q36311839-446D78B0-A6C9-433B-A964-078DE8C65CA8

Q36311839-6547CF55-016C-440E-8106-2166AD3BA144

Q36311839-660FC7C8-B075-4A88-99EB-00E1DDCD7596

Q36311839-6BBDC3A6-569B-4162-9E16-2B82175379E8

Q36311839-6E85F720-8E24-46BD-92B6-A913B3A85FCA

Q36311839-81CD7AF5-D587-4E72-9D16-847432172B92

Q36311839-B446F788-82BB-498C-9795-74DB7C7D2F1F

Q36311839-BB7D0EFD-BFF8-4C3B-BF7E-A0273940CAF6

Q36311839-BF7B5F93-5332-41A4-9F21-2FBA740B1502

P304

Q36311839-2D4E5D95-E8AB-49E5-ACF4-4D55CDB09E0E

P31

Q36311839-A2A816B5-C118-455A-8A6C-B8ACF52BD3C3

P356

Q36311839-1B5535B4-ACA4-41E2-B702-DAAD3C7B989A

P407

Q36311839-35CAC9A1-2905-4E7F-92ED-7EEF6EDBCC2F

P433

Q36311839-1313DEB6-1C2A-459D-9490-A81C04F2D1E4

P478

Q36311839-87B9B221-59EC-46BC-A460-3F7F839DAC16

P577

Q36311839-37FC5AB9-9851-41FC-B841-66B1861DAA3F

P698

Q36311839-FD58AEE1-B221-4DE2-9458-FD0C9450230D

P932

Q36311839-ACE23D2D-5987-43AC-83D6-AE5FCB6148DD

P356

0003-4819-156-10-201205150-00013

P1433

Annals of Internal Medicine

P1476

Reactivation of hepatitis B du ...... ntially fatal yet preventable.

@en

P2093

Anna S F Lok

http://www.w3.org/2001/XMLSchema#string

Brian J McMahon

http://www.w3.org/2001/XMLSchema#string

John W Ward

http://www.w3.org/2001/XMLSchema#string

Robert P Perrillo

http://www.w3.org/2001/XMLSchema#string

T Jake Liang

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic hepatitis B: update 2009

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.

An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

Reactivation of hepatitis B.

Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population.

P304

743-745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-156-10-201205150-00013

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

156

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22586011

http://www.w3.org/2001/XMLSchema#string

P932

3469313

http://www.w3.org/2001/XMLSchema#string